Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future | Zendy

Sharif Halim | Zendy; L. Kristin Newby | Zendy; E. Magnus Ohman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future

Author(s) -

Sharif Halim,

L. Kristin Newby,

E. Magnus Ohman

Publication year - 2011

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2011.165787

Subject(s) - clinical trial , biobank , medicine , biomarker discovery , disease , precision medicine , intensive care medicine , clinical endpoint , clinical practice , clinical study design , bioinformatics , pathology , physical therapy , biology , proteomics , biochemistry , gene

Cardiovascular (CV) clinical trials are instrumental in understanding treatment effects and offer insights into the natural progression of CV disease. Biomarkers are a critical component of patient selection, end point definition, and safety monitoring, and clinical trials provide a platform for the discovery and validation of new biomarkers that may augment the understanding of disease mechanisms, risk stratification, and/or clinical decision-making.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research